The Quantellect read.As of Nov 19, 2026, 20 active firms cover Tandem Diabetes Care Inc: 9 rate it Buy or better, 11 sit at Neutral, and 0 rate it Sell or worse, a neutral consensus. The target range is very wide, $15.50 to $50.00 (about 3.2x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $26.14 sits 53% above the current $17.05. The rating mix has stayed broadly stable, with Buy-side ratings easing from 11 to 9 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.15 next quarter toward $0.10 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS20 active firms
Neutral
Strong Buy00%
Buy945%
Neutral1155%
Sell00%
Strong Sell00%
Based on 20 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$26.14
+53.3% upside
Average target across 18 active firms as of Nov 19, 2026 vs $17.05 current
Highest Target$50.00
Average Target$26.14
Lowest Target$15.50
Detailed analyst forecasts for TNDM
Showing 1–21 of 21 named analysts shown · 20 active firms in the rating projection
As of Nov 19, 2026, 9 of 20 active firms rate TNDM a Buy (11 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
TNDM EPS & revenue forecast
EPS · NEXT QUARTER
$-0.15
Range $-0.25 – $0.00 · 16 analysts · -52% YoY
Next period, 16 analysts expect Tandem Diabetes Care Inc to earn $-0.15 a share (range $-0.25 – $0.00), versus $-0.30 a year earlier. Full-year consensus is $-0.60, growing to $0.10 the year after.
REVENUE · NEXT QUARTER
$263.8M
Range $252.0M – $277.3M · 16 analysts · +7% YoY
Revenue is expected to reach $263.8M (range $252.0M – $277.3M), +6.7% year-over-year. Full-year consensus is $1.1B, rising to $1.2B next year.
Top analysts covering Tandem Diabetes Care Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TNDM.
#1
Joanne Wuensch
Citigroup · Rank #35
Neutral
No targeton TNDM
Overall win rate
51%
+ Follow
#2
Anthony Petrone
Mizuho · Rank #121
Neutral
$20.00+17.3% to target
Overall win rate
45%
+ Follow
#3
Jonathan Block
Stifel · Rank #294
Neutral
$22.00+29.0% to target
Overall win rate
36%
+ Follow
#4
William Plovanic
Canaccord Genuity · Rank #370
Buy
$40.00+134.6% to target
Overall win rate
38%
+ Follow
#5
Bruce Jackson
Benchmark · Rank #487
Neutral
No targeton TNDM
Overall win rate
36%
+ Follow
TNDM stock forecast FAQ
What is TNDM's average 12-month price target?+
The 18 active firms with a live target average $26.14 for Tandem Diabetes Care Inc over the next 12 months, ranging from a $50.00 high to a $15.50 low, as of Nov 19, 2026.
Is TNDM stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 20 active firms as of Nov 19, 2026, 9 rate it Buy or Strong Buy, 11 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for TNDM?+
The Street-high target is $50.00 (Lake Street), and the Street-low is $15.50 (Deutsche Bank). The average of all 18 active-firm targets is $26.14.
How many active Wall Street firms cover TNDM?+
20 active firms have a recognized rating on Tandem Diabetes Care Inc as of Nov 19, 2026, and 18 active firms carry a live 12-month price target.
Who is the most accurate analyst covering TNDM?+
Among analysts who currently cover TNDM, Joanne Wuensch of Citigroup has the strongest overall Quantellect track record (Rank #35). Their current call is Neutral.
What is Tandem Diabetes Care Inc's projected EPS for next quarter?+
The consensus estimate is $-0.15 per share (range $-0.25 – $0.00) across 16 analysts. Full-year EPS is projected at $-0.60, rising to $0.10 the following year.
How much revenue is Tandem Diabetes Care Inc expected to report next quarter?+
Consensus revenue is $263.8M (range $252.0M – $277.3M). Full-year revenue is projected at $1.1B, growing to $1.2B next year.
Have analysts been upgrading or downgrading TNDM lately?+
As of Nov 19, 2026, 9 of 20 active firms rate TNDM a Buy (11 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TNDM calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.